Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, talks on progression independent of relapse activity in multiple sclerosis (MS). The current classification categorizes MS as progressive when it has a score of 4 on the Expanded Disability Status Scale (EDSS) and is based on visible relapse-associated progression. However, it has been shown that a much higher proportion of the disability in MS is accumulated due to silent progression, which is independent of relapse activity. This silent progression is especially important in the early stages of the disease. This interview took place during the XXV World Congress of Neurology.
Dr Tintoré has received compensation for:
Consulting services and speaking honoraria from Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Jansen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals.
Receipt grants and research supports from Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000. Biogen-Idec, Novartis.